Zobrazeno 1 - 10
of 254
pro vyhledávání: '"JOJI TANI"'
Autor:
Tetsu Tomonari, Joji Tani, Yasushi Sato, Hironori Tanaka, Akihiro Morishita, Koichi Okamoto, Yutaka Kawano, Masahiro Sogabe, Hiroshi Miyamoto, Tetsuji Takayama
Publikováno v:
JGH Open, Vol 8, Iss 10, Pp n/a-n/a (2024)
Abstract Background and Aims We aimed to evaluate the efficacy and safety of durvalumab plus tremelimumab (Dur + Tre) combination therapy in patients with unresectable hepatocellular carcinoma (uHCC) in clinical practice. Methods We retrospectively e
Externí odkaz:
https://doaj.org/article/86a948e52f61412e9e5dbc9d88062c02
Autor:
Tomoko Tadokoro, Joji Tani, Takushi Manabe, Kei Takuma, Mai Nakahara, Kyoko Oura, Shima Mimura, Koji Fujita, Takako Nomura, Asahiro Morishita, Hideki Kobara, Takashi Himoto, Masafumi Ono, Tsutomu Masaki
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Portal vein thrombosis (PVT) worsens the long-term prognosis of patients with cirrhosis; however, the optimal treatment remains to be determined. Reports on the efficacy of direct oral anticoagulants are increasing, and further evidence is n
Externí odkaz:
https://doaj.org/article/edf0293d1b7b41aca4d8da2b8ed176f0
Autor:
Tomoko Tadokoro, Takako Nomura, Koji Fujita, Takushi Manabe, Kei Takuma, Mai Nakahara, Kyoko Oura, Shima Mimura, Joji Tani, Asahiro Morishita, Hideki Kobara, Masafumi Ono, Tsutomu Masaki
Publikováno v:
BMC Gastroenterology, Vol 24, Iss 1, Pp 1-8 (2024)
Abstract Background Hepatocellular carcinoma (HCC) in autoimmune hepatitis (AIH) was considered rare but is increasing with prolonged prognosis. Its impact on the overall prognosis of AIH is unknown, and treatment has not been established. Aim To inv
Externí odkaz:
https://doaj.org/article/b1e1db6200a24ae49e2fc299f5bec07e
Autor:
Kyoko Oura, Asahiro Morishita, Kei Takuma, Mai Nakahara, Tomoko Tadokoro, Koji Fujita, Shima Mimura, Joji Tani, Masafumi Ono, Takashi Himoto, Tsutomu Masaki
Publikováno v:
Cancer Medicine, Vol 12, Iss 24, Pp 22023-22037 (2023)
Abstract Aim Indications of drug therapies to elderly patients with hepatocellular carcinoma (HCC) should be carefully determined. The current study assessed the safety and efficacy of molecular targeted agents (MTAs) in the elderly patients with HCC
Externí odkaz:
https://doaj.org/article/1f9fc393f2c049ff98af5d20111cb879
Autor:
Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Keisuke Yokohama, Hiroki Nishikawa, Takashi Nishimura, Noritomo Shimada, Kazuhito Kawata, Hisashi Kosaka, Atsushi Naganuma, Yutaka Yata, Hideko Ohama, Hidekatsu Kuroda, Kazunari Tanaka, Takaaki Tanaka, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Taeang Arai, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Masaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, the Real‐life Practice Experts for HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan)
Publikováno v:
Cancer Medicine, Vol 12, Iss 24, Pp 21680-21693 (2023)
Abstract Aim This retrospective study compared the impact of atezolizumab plus bevacizumab (Atez/Bev) and lenvatinib (LEN) on the liver function in patients with hepatocellular carcinoma. Methods We included 526 patients who received Atez/Bev and 731
Externí odkaz:
https://doaj.org/article/47d83858206f4fedb8133cae3683b6fd
Autor:
Miwa Tatsuta, Masafumi Ono, Shungo Kimura, Kaori Zuigyo, Yudai Sato, Akemi Tomida, Mitsuyoshi Kobayashi, Ritsuko Yoshikawa, Satoshi Murao, Joji Tani, Asahiro Morishita, Hideki Kobara, Takashi Himoto, Tsuyoshi Maeta, Yoshihiro Mori, Fumikazu Kohi, Tsutomu Masaki
Publikováno v:
JGH Open, Vol 7, Iss 12, Pp 990-997 (2023)
Abstract Background and Aim Nonalcoholic fatty liver disease (NAFLD) is closely associated with metabolic syndrome. This study was performed to examine the association between NAFLD and each factor of metabolic syndrome and to identify the factors th
Externí odkaz:
https://doaj.org/article/70a00d6c9eb14da892fb7be30fc611bb
Publikováno v:
Microorganisms, Vol 12, Iss 9, p 1926 (2024)
Chronic hepatitis C virus (HCV) infection is associated with an increased risk of extrahepatic cancers, particularly non-Hodgkin lymphoma. The introduction of direct-acting antivirals (DAAs) has revolutionized HCV therapy, resulting in high cure rate
Externí odkaz:
https://doaj.org/article/0032883a2bf04a9e9f66bece70907b2d
Autor:
Yudai Sato, Tomoko Tadokoro, Hiroki Yamana, Hiraki Akai, Kei Takuma, Naoki Fujita, Mai Nakahara, Kyoko Oura, Koji Fujita, Joji Tani, Hideki Kamada, Asahiro Morishita, Hideki Kobara, Seiko Kagawa, Reiji Haba, Keiichi Okano, Tsutomu Masaki
Publikováno v:
DEN Open, Vol 4, Iss 1, Pp n/a-n/a (2024)
Abstract Hepatocellular carcinoma invasion of the bile duct is rare and has a poor prognosis. A 77‐year‐old man presented at the emergency department with persistent pain in the right hypochondrium. Blood tests and imaging studies revealed a 70
Externí odkaz:
https://doaj.org/article/fc380b8c52934850ae901bdfcd046599
Autor:
Hideko Ohama, Atsushi Hiraoka, Toshifumi Tada, Masashi Hirooka, Kazuya Kariyama, Takeshi Hatanaka, Joji Tani, Koichi Takaguchi, Masanori Atsukawa, Ei Itobayashi, Takashi Nishimura, Kunihiko Tsuji, Kazuto Tajiri, Toru Ishikawa, Satoshi Yasuda, Hidenori Toyoda, Shinya Fukunishi, Chikara Ogawa, Satoru Kakizaki, Noritomo Shimada, Atsushi Naganuma, Kazuhito Kawata, Hisashi Kosaka, Hidekatsu Kuroda, Tomomitsu Matono, Yutaka Yata, Hironori Ochi, Fujimasa Tada, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Keisuke Yokohama, Hiroki Nishikawa, Michitaka Imai, Yohei Koizumi, Shinichiro Nakamura, Hiroko Iijima, Masaki Kaibori, Yoichi Hiasa, Takashi Kumada, Representing the Real‐life Practice Experts for HCC Study Group with Hepatocellular Carcinoma experts from 48 clinics in Japan (RELPEC/HCC 48 Group)
Publikováno v:
Cancer Reports, Vol 7, Iss 4, Pp n/a-n/a (2024)
Abstract Aims The aim of the present study was to elucidate detailed parameters for prediction of prognosis for patients with unresectable hepatocellular carcinoma (uHCC) receiving atezolizumab plus bevacizumab (Atez/Bev) treatment. Methods A total o
Externí odkaz:
https://doaj.org/article/db2c34e45940412fa92f5beffa4e949a
Autor:
Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Francesca Bergamo, Elisabeth Amadeo, Francesco Vitiello, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Massimo Iavarone, Giuseppe Cabibbo, Margarida Montes, Francesco Giuseppe Foschi, Caterina Vivaldi, Caterina Soldà, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Hiraoka, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Mara Persano, Silvia Foti, Silvia Camera, Bernardo Stefanini, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini, Margherita Rimini
Publikováno v:
Liver Cancer (2024)
Introduction The impact of etiology on response to immunotherapy in advanced hepatocellular carcinoma (HCC) is being debated, with contrasting findings between early and recent post-hoc analyses of IMbrave-150 and metanalyses of clinical trials of PD
Externí odkaz:
https://doaj.org/article/3da67a4e9b81471598019e46c12fc527